Amgen Inc. $AMGN Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 8.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 2,092,255 shares of the medical research company’s stock after selling 202,929 shares during the period. California Public Employees Retirement System’s holdings in Amgen were worth $590,434,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AMGN. West Family Investments Inc. lifted its holdings in shares of Amgen by 1.1% in the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after buying an additional 30 shares during the period. Viawealth LLC boosted its stake in shares of Amgen by 0.4% in the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after buying an additional 30 shares during the last quarter. LOM Asset Management Ltd grew its holdings in Amgen by 1.2% during the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock worth $721,000 after acquiring an additional 30 shares during the period. TAGStone Capital Inc. raised its position in Amgen by 0.8% during the third quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after acquiring an additional 32 shares in the last quarter. Finally, BBR Partners LLC raised its position in Amgen by 0.5% during the third quarter. BBR Partners LLC now owns 7,117 shares of the medical research company’s stock valued at $2,008,000 after acquiring an additional 32 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Trading Down 0.4%

Shares of AMGN stock opened at $366.21 on Friday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The company has a market cap of $197.41 billion, a price-to-earnings ratio of 25.74, a PEG ratio of 3.63 and a beta of 0.45. The stock has a 50 day simple moving average of $357.73 and a 200-day simple moving average of $325.42. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter last year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. Amgen’s dividend payout ratio (DPR) is 70.84%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen will add medicines to the TrumpRx prescription site, which could expand patient access and volume for listed products if uptake follows; this is a near-term distribution win. GSK and Amgen to add medicines to TrumpRx, Fox Business reports
• Positive Sentiment: Product momentum — coverage highlights MariTide and osteoporosis treatments as sales drivers that have helped fuel recent rallies, supporting revenue growth expectations. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Institutional demand: Amgen is a notable holding in income-oriented funds, which supports steady shareholder demand given its long dividend track record. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Operational tie-ins: Rapid Micro Biosystems notes Amgen’s expansion of its Growth Direct system rollout — a small but constructive signal of ongoing manufacturing/capacity investments. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Neutral Sentiment: Analyst action: Jefferies issued a Hold on AMGN, a neutral rating that can dampen upside momentum vs. more bullish calls. Amgen (NASDAQ:AMGN) Earns Hold Rating from Analysts at Jefferies Financial Group
• Neutral Sentiment: Press roundups: Amgen appears in broader mega-cap watchlists and industry write-ups — visibility is high but these pieces are more contextual than catalytic. 2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
• Negative Sentiment: Dividend/valuation concerns: Independent analysis flags high debt levels, weaker risk-adjusted returns and questions around dividend attractiveness at current prices — these are potential longer‑term headwinds for the stock’s re-rating. Dividend Stock Analysis – Amgen, Inc.

Wall Street Analysts Forecast Growth

Several research firms have commented on AMGN. Truist Financial upped their price objective on Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research report on Thursday, January 8th. Argus boosted their target price on shares of Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Wall Street Zen downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. BMO Capital Markets raised their price target on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Finally, Cantor Fitzgerald lifted their price objective on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $354.00.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.